These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 24370812

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P.
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P.
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication.
    King AJ, Rotchford AP.
    JAMA Ophthalmol; 2016 Jul 01; 134(7):742-7. PubMed ID: 27148831
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M, Otani S, Kozaki J, Unoki K, Takeuchi M, Minami K, Miyata K.
    J Glaucoma; 2012 Jan 01; 21(1):60-4. PubMed ID: 21278589
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. First-in-human continuous 24-hour measurement of intraocular pressure and ocular pulsation using a novel contact lens sensor.
    Wasilewicz R, Varidel T, Simon-Zoula S, Schlund M, Cerboni S, Mansouri K.
    Br J Ophthalmol; 2020 Nov 01; 104(11):1519-1523. PubMed ID: 32075818
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
    Gandolfi S, Paredes T, Goldberg I, Coote M, Wells A, Volksone L, Pillai MR, Stalmans I, Denis P, Travoprost Bak-Free Clinical Study Group.
    Eur J Ophthalmol; 2012 Nov 01; 22(1):34-44. PubMed ID: 22167541
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Latanoprost treatment differentially affects intraocular pressure readings obtained with three different tonometers.
    Sánchez-Barahona C, Bolívar G, Katsanos A, Teus MA.
    Acta Ophthalmol; 2019 Dec 01; 97(8):e1112-e1115. PubMed ID: 31184426
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension.
    Peace JH, Ahlberg P, Wagner M, Lim JM, Wirta D, Branch JD.
    Am J Ophthalmol; 2015 Aug 01; 160(2):266-274.e1. PubMed ID: 25935098
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.